Literature DB >> 2426298

The significance of alpha-subunit as a tumor marker for gonadotropin-producing pituitary adenomas.

R Demura, K Jibiki, O Kubo, E Odagiri, H Demura, K Kitamura, K Shizume.   

Abstract

We studied gonadotropin hormone alpha-subunit and gonadotropin secretion in four patients with gonadotropin-producing pituitary adenomas. All four patients had elevated plasma alpha-subunit levels, ranging from 2.8-8.5 ng/ml (normal, less than 0.5 ng/ml). alpha-Subunit responses to LHRH were less than those in seven patients with primary gonadal failure. The relative proportions of the gonadotropin and alpha-subunit peaks in one patient were the same before and after LHRH administration, based on gel filtration studies of plasma. The alpha-subunit levels decreased little during testosterone treatment in the two adenoma patients so treated. Immunohistochemical study of the adenomas from two patients demonstrated definite staining with alpha-subunit and gonadotropin antisera. Elevated plasma levels of alpha-subunit and its relative unresponsiveness to LHRH stimulation or testosterone suppression suggest that the alpha-subunit originated in tumor tissue and that its measurement is useful for the diagnosis of a gonadotropin-producing tumor in patients with elevated plasma levels of LH and/or FSH.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426298     DOI: 10.1210/jcem-63-3-564

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

Review 2.  Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.

Authors:  Mansur E Shomali; Laurence Katznelson
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

3.  Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.

Authors:  S Damjanović; D Micić; V Popović; M Petakov; A Kendereski; M Sumarac; D Manojlović; J Mićić
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

4.  HGH, PRL and beta HCG/beta LH gene expression in clinically inactive pituitary adenomas detected by in situ hybridization.

Authors:  E Bäz; W Saeger; H Uhlig; S Fehr; D K Lüdecke
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

5.  Serum FSH bioactivity and inhibin levels in patients with gonadotropin secreting and nonfunctioning pituitary adenomas.

Authors:  S Borgato; L Persani; R Romoli; D Cortelazzi; A Spada; P Beck-Peccoz
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

6.  Polymorphism of thyrotropin and alpha subunit in human pituitary adenomas.

Authors:  I Sergi; G Medri; M J Papandreou; G Gunz; P Jaquet; C Ronin
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

7.  Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.

Authors:  C Blanco; T Lucas; J Alcañiz; N Davila; P Serrano; B Barcelò; J Estrada
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.